Uterine Cancer Mortality on the Rise, but Research Remains Underfunded
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to researchers.
Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.
Anlotinib enhances the efficacy of pembrolizumab in patients with recurrent or refractory high-grade serous ovarian cancer, a phase 2 study suggests.
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy appears safe and effective for patients with advanced cervical cancer.
Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.
Cryocompression can reduce subjective peripheral neuropathy in patients with gynecologic cancer undergoing chemotherapy, a study suggests.
Nerve-sparing retroperitoneal lymph node dissection appears safe and effective for patients with low-volume metastatic seminoma.
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Treatment with radiolabeled J591 plus ketoconazole and hydrocortisone may delay time to metastasis in patients with high-risk nmCRPC.